Applied Molecular Transport Appoints Earl Douglas as General Counsel
22 3월 2021 - 9:00PM
Applied Molecular Transport Inc. (
Nasdaq: AMTI)
(AMT), a clinical-stage biopharmaceutical company, today announced
that it has appointed Earl Douglas as General Counsel. In his new
role, Earl will assume leadership responsibilities for all legal
activities of the Company. He will become a member of the AMT
Executive Team, reporting to chief executive officer and co-founder
of AMT, Tahir Mahmood, Ph.D.
“I am delighted to welcome Earl as our general
counsel and latest member of our executive management team,” stated
Tahir Mahmood, Ph.D. “Earl brings extensive legal and strategic
advisory experience that will be invaluable as we continue to
advance our promising pipeline of novel, oral biologic medicines.
He is joining AMT at a critical time for the company, as we look
forward to sharing top-line oral AMT-101 data readouts from the
four Phase 2 trials from our comprehensive clinical program
beginning in the second half of 2021 and as our second program,
oral AMT-126, progresses through the clinic.”
Mr. Douglas joins with more than 30 years of
deep experience, leading and building legal organizations for
biotechnology and medical device organizations. Mr. Douglas most
recently served as general counsel at Kiverdi. He has also served
as general counsel and corporate secretary at BioMimetic
Therapeutics (acquired by Wright Medical Group), Spinal Dynamics
(acquired by Medtronic), and OPX Biotechnologies (acquired by
Cargill). He also previously served as Counsel at Wilson Sonsini
Goodrich & Rosati, and earlier in his career, practiced as an
associate with Weil, Gotshal & Manges.
Mr. Douglas earned a B.S. in chemical engineering from the
Massachusetts Institute of Technology and holds a J.D. from
Columbia University School of Law.
“I am thrilled to be joining AMT at such an
important point in the Company’s growth,” said Earl Douglas,
general counsel of AMT. “I look forward to supporting the Company’s
future progress with this accomplished team.”
About AMT-101AMT-101 is a novel
GI-selective, oral fusion of hIL-10 and AMT’s proprietary carrier
molecule, which is currently being developed in four Phase 2
clinical trials in inflammatory bowel diseases and rheumatoid
arthritis. AMT-101 is designed to cross the intestinal epithelium
barrier with limited entry into the bloodstream, thereby focusing
hIL-10 at the primary site of inflammation for UC and potentially
avoiding the side effects observed with systemic administration. By
design, AMT-101 is actively transported through the IE barrier into
the GI tissue, the primary site of inflammation in UC.
About AMT-126AMT-126 is a novel
GI-selective, oral fusion of hIL-22 and AMT’s proprietary carrier
molecule currently in development for diseases related to
intestinal epithelial (IE) barrier defects. IL-22 is a cytokine
that repairs structural and functional defects of the IE barrier
and induces microbial defense. AMT-126 is designed to act locally
on the epithelial cells of the intestinal tissue, thereby repairing
the IE barrier and supporting mucosal healing, potentially
translating into clinically meaningful improvements in a broad
range of GI-focused, peripheral inflammatory and other
diseases.
About Applied Molecular Transport
Inc.Applied Molecular Transport Inc. is a clinical-stage
biopharmaceutical company leveraging its proprietary technology
platform to design and develop a pipeline of novel oral biologic
product candidates to treat autoimmune, inflammatory, metabolic,
and other diseases. AMT’s proprietary technology platform allows it
to exploit existing natural cellular trafficking pathways to
facilitate the active transport of diverse therapeutic modalities
across the intestinal epithelium (IE) barrier. Active transport is
an efficient mechanism that uses the cell’s own machinery to
transport materials across the IE barrier. AMT believes that its
ability to exploit this mechanism is a key differentiator of its
approach. AMT is developing additional oral biologic product
candidates in patient-friendly oral forms that are designed to
either target local gastrointestinal tissue or enter systemic
circulation to precisely address the relevant biology of a
disease.
AMT’s headquarters, internal GMP manufacturing
and lab facilities are located in South San Francisco, CA. For
additional information on AMT, please visit www.appliedmt.com.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995.
Forward-looking statements generally relate to future events or
AMT’s future plans, strategy and performance. Such statements
include, but are not limited to, the potential of, and expectations
regarding AMT’s technology platform, AMT-101 and AMT-126,
statements regarding AMT’s pipeline of product candidates, AMT’s
Phase 2 clinical trials for AMT-101 including the timing of data
readouts from such trials, AMT’s ability to leverage its technology
to expand its pipeline and Mr. Douglas’ potential contributions to
AMT. Such statements are subject to numerous important factors,
risks and uncertainties that may cause actual events or results to
differ materially, including those more fully described under the
section entitled “Risk Factors” in documents the company files from
time to time with the Securities and Exchange Commission. These
forward-looking statements are made as of the date of this press
release, and AMT assumes no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements, except as required by law.
Investor Relations Contact:Andrew ChangHead,
Investor Relations & Corporate
Communicationsachang@appliedmt.com
Media Contacts:Alexandra SantosWheelhouse Life
Science Advisorsasantos@wheelhouselsa.com
Aljanae ReynoldsWheelhouse Life Science
Advisorsareynolds@wheelhouselsa.com
Applied Molecular Transp... (NASDAQ:AMTI)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Applied Molecular Transp... (NASDAQ:AMTI)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024